Clinical Nutrition For Chronic Kidney Diseases Market (2026 - 2033)

Clinical Nutrition for Chronic Kidney Diseases Market Summary

The global clinical nutrition for chronic kidney diseases market size was valued at USD 1.8 billion in 2025 and is projected to grow from USD 1.9 billion in 2026 to USD 2.9 billion by 2033, at a CAGR of 6.0% from 2026 to 2033. The North American dominated the market, accounting for a revenue share of 32.0% in 2025, owing to increasing demand for clinical nutrition among individuals with chronic kidney disease (CKD). Growing healthcare expenditure, an expanding geriatric population, and favorable clinical guidelines supporting nutrition therapy for CKD patients are expected to drive growth in the global market.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

CKDs pose a significant challenge, particularly in low- and middle-income countries that are ill-prepared to manage their effects. The condition has become one of the primary causes of death globally and is among the few non-communicable diseases that have seen a rise in related fatalities over the last two decades. The substantial number of people affected and the severe negative consequences of CKD necessitate increased initiatives for improved prevention and treatment.

High blood pressure and diabetes are the two most common causes of developing CKD. The rising prevalence of malnutrition among the adult population, increase in the instances of obesity, and the rising chronic diseases such as cancer and diabetes are the major factors boosting the market growth. Oral clinical nutrition for CKD includes vitamins, proteins, and carbohydrates in powder, liquid, and semi-solid forms. Key market players manufacturing oral clinical nutrition products are introducing new flavors to enhance taste, thereby capturing a larger customer base.

Rising awareness among the public and healthcare professionals about treating such deficiencies has increased demand for oral clinical nutrition products. According to the Centers for Disease Control and Prevention (CDC), approximately 35.5 million adults in the U.S., or about 14% of the population, were estimated to have CKD as of 2023. Growing awareness of CKD and the importance of nutritional management in slowing disease progression has contributed to increasing demand for specialized clinical nutrition products. Unhealthy lifestyles have led to an increasing burden of health issues such as lack of nutrition, obesity, and poor immunity, leading to the rise of chronic, neurological, and autoimmune diseases.

Analyst Perspective

The market is expected to grow steadily during the forecast period, driven by the rising prevalence of CKD, an aging population, and increasing awareness of the role of nutrition in disease management. The need to address CKD-related nutritional challenges, including protein-energy wasting and fluid and electrolyte imbalance, is fueling demand for disease-specific nutritional products. Manufacturers are focusing on developing innovative oral, enteral, and parenteral nutrition solutions, while supportive clinical guidelines and the growing adoption of personalized nutrition are further driving market growth. In addition, strategic initiatives such as mergers, acquisitions, product portfolio expansion, and investments in medical nutrition technologies are expected to create significant growth opportunities over the coming years.

Product Insights

The oral clinical nutrition segment accounted for the largest market share of 51.0% in 2025. Increased preference for oral products, commercial viability, and supportive initiatives are key factors driving demand for orally administered medical foods. Furthermore, the growing manufacturing of oral products in the form of pre-thickened products, powders, and pills is anticipated to fuel the segment.

Parenteral feeding formulas are expected to register the fastest growth over the forecast period. Patients with CKD might experience malnutrition and oral feeding challenges and would require parenteral nutrition as an alternative. In acute or chronic renal failure, particularly among patients undergoing extracorporeal renal replacement therapies such as hemodialysis or peritoneal dialysis, parenteral nutrition may be crucial due to the severity of the underlying condition and associated catabolism.

Stage Insights

The adults segment accounted for the largest market share, at around 83.0% in 2025, owing to the rising prevalence of nutritional deficiencies and malnutrition among adults. Adults may experience decreased muscle strength and vitamin and calcium deficiencies, particularly among women over 30 years old. Furthermore, they can face apathy, weakened immunity, high blood pressure, and fatigue. These factors contribute to nutritional deficiencies in the adult population.

The adults segment is also anticipated to grow the fastest over the forecast period. According to the National Center for Biotechnology Information (NCBI), an estimated 843.6 million people worldwide are affected by chronic kidney disease (CKD) across stages 1–5. In addition, the Centers for Disease Control and Prevention (CDC) reports that CKD affects approximately 34% of adults aged 65 years and older, compared with 12% of those aged 45–64 years and 6% of adults aged 18–44 years. The growing global burden of CKD, particularly among the aging population, is expected to drive demand for specialized clinical nutrition products for disease management. Therefore, the growing incidence of CKDs worldwide underscores the importance of collaborative initiatives aimed at preventing and managing CKD and its associated complications at a global level.

Sales Channel Insights

The institutional sales segment accounted for the largest market share of around 41.0% in 2025. The sales channel includes commercial sales to government organizations, hospitals, and research institutes. The increased prevalence of CKDs globally contributes to a surge in patient visits to medical facilities seeking diagnosis and treatment options. Consequently, as patient awareness rises, the trend toward using official hospital channels to obtain CKD nutrition prescriptions has increased.

The online sales segment is anticipated to witness the fastest growth rate over the forecast period. Advancements in telemedicine have enabled the global distribution of clinical nutrition products, allowing manufacturers to broaden their market reach and cater to underserved communities. Thus, online sales have surged due to rising customer demand for CKD supplements across various online platforms and stores.

Regional Insights

North America dominated the market, accounting for a revenue share of 32.0% of revenue in 2025. The growth in this region can be attributed to its well-developed healthcare infrastructure and supportive reimbursement policies. Moreover, significant public and private investments in healthcare have contributed to the market’s expansion in the area.

To learn more about this report, Download Free Sample Report

U.S. Clinical Nutrition for Chronic Kidney Diseases Market Trends

The clinical nutrition for chronic kidney diseases market in the U.S. dominated the North American region in 2025. Moreover, the country’s focus on research initiatives and its significant investment in developing supplemental alternatives have asserted its dominance in the market.

Europe Clinical Nutrition for Chronic Kidney Diseases Market Trends

The clinical nutrition for chronic kidney diseases market in Europe was the second-largest regional market in 2025. The European market is driven by the rising burden of kidney disease and increasing adoption of disease-specific nutritional management. According to the European Renal Association (ERA), an estimated 75 million people in Europe are living with CKD, and the disease is projected to become the fifth leading cause of death globally by 2040. The European Society for Clinical Nutrition and Metabolism (ESPEN) continues to promote personalized nutrition therapy as a key component of CKD management. The growing prevalence of CKD and increasing awareness of the benefits of specialized clinical nutrition are expected to drive demand for renal nutrition products across major European markets, including the UK, Germany, Spain, and Italy.

The UK clinical nutrition for chronic kidney diseases market occupied the largest revenue share in Europe and is anticipated to witness the fastest CAGR over the forecast period. Lifestyle disorders such as obesity and heart disease are anticipated to propel market growth in the country.

The clinical nutrition for chronic kidney diseases market in Germany was the second-largest in Europe in 2025. It is anticipated to register lucrative growth in the Europe market over the forecast period. The country is known for its pharmaceutical prowess and high-quality standards. The German Society for Nutritional Medicine (DGEM) offers recommendations on the appropriate use of vitamins and trace elements when routine enteral nutrition fails to meet daily requirements. In cases where supplemental parenteral nutrition becomes necessary, their guidance ensures appropriate usage.

Asia Pacific Clinical Nutrition for Chronic Kidney Diseases Market Trends

The clinical nutrition for chronic kidney diseases market in the Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033. Moreover, Japan and China have a significant elderly population, which is at a high risk of chronic conditions. Nutritional deficiencies are more common among the geriatric population, which is expected to boost demand for medical foods in the Asia-Pacific region. In the coming years, the Asia-Pacific region is expected to become a crucial market due to the increasing prevalence of CKD among older adults and the continued growth of healthcare infrastructure.

China clinical nutrition for chronic kidney diseases market accounted for the largest share of market revenue in Asia Pacific in 2025 and is expected to grow at the fastest CAGR over the forecast period. According to an NCBI systematic review and analysis, up to an estimated 434.3 million adults had CKD in Eastern, Southern, and South-Eastern Asia, with China having the highest number of people with CKD. Moreover, the presence of manufacturing facilities by major global players in China has made CKD supplements more accessible.

The clinical nutrition for chronic kidney diseases market in Japan accounted for the second-largest revenue share in 2025 and is anticipated to witness robust growth over the forecast period. With rising per capita healthcare expenditure, patients with CKD in Japan have become more aware of the nutrients they require and are thus opting for clinical nutrition supplements as self-care measures.

India clinical nutrition for chronic kidney diseases market is anticipated to witness the fastest growth during the forecast period. Clinical nutrition is essential in India, primarily aiding dietary adherence among patients with CKD. The expansion of global players in the region, such as Ajanta Pharma Limited, Hexagon Nutrition Limited, Nutricia Limited, RPG Life Sciences, Mankind Pharma Ltd., and Nestle Health Science S.A., which manufacture and supply CKD supplements to the region, has contributed significantly to market growth.

Key Clinical Nutrition for Chronic Kidney Diseases Company Insights

The market is concentrated, with global clinical nutrition companies accounting for a large share. Companies in the global market are collaborating with regional players and expanding globally to expand their services and product portfolios. Some key players operating in the global market include Abbott Nutrition, Nestlé Health Science S.A., Danone Nutricia, Fresenius Kabi AG, and Mead Johnson & Company, LLC.

Companies in the clinical nutrition for chronic kidney disease market have pursued a range of strategic initiatives to sustain growth, including mergers, collaborations, product development, and global and regional expansion. For instance, global players in the market are collaborating with local distributors and sales channels to expand their reach.

Clinical Nutrition for Chronic Kidney Diseases Companies:

The following are the leading companies in the clinical nutrition for chronic kidney diseases market. These companies collectively hold the largest market share and dictate industry trends.

• Abbott Nutrition

• Pfizer Inc.

• Bayer AG

• Nestle Health Science S.A.

• GlaxoSmithKline plc

• Baxter International Inc.

• Otsuka Holdings Co., Ltd.

• Mead Johnson & Company, LLC

• Danone Nutricia

• Victus, Inc.

Recent Developments

• In May 2025, Danone completed the acquisition of a majority stake in Kate Farms, a U.S.-based provider of plant-based medical and specialized nutrition products. The acquisition strengthens Danone’s specialized nutrition portfolio and expands its presence in medical nutrition by enhancing its offerings for patients with disease-specific nutritional needs.

• In October 2025, Nestlé Health Science announced a strategic partnership with the University of California, Davis Innovation Institute for Food & Health to accelerate innovation in nutrition and health science. The collaboration focuses on advancing research in precision nutrition and developing science-based nutritional solutions to address specialized healthcare needs.

Global Clinical Nutrition for Chronic Kidney Diseases Market Report Segmentation

This report forecasts revenue growth at the global, country, and regional levels, and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical nutrition for chronic kidney diseases market report based on product, stage, sales channel, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Oral Nutrition

  • Parenteral Nutrition

  • Enteral Feeding Formulas

• Stage Outlook (Revenue, USD Billion, 2021 - 2033)

  • Adult

  • Pediatric

• Sales Channel Outlook (Revenue, USD Billion, 2021 - 2033)

  • Online

  • Retail

  • Institutional Sales

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait